Fever for days: A challenging case of dalbavancin-induced fever

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Medicine

Background:

• Dalbavancin is a lipoglycopeptide antibiotic for Gram-positive bacterial infections.
• Its long half-life allows for extended treatment durations, reducing the need for prolonged IV therapy.
• Dalbavancin is approved for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

Observation:

• A case report of a 27-year-old male patient is presented.
• The patient developed fever during treatment for Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia.
• Fever emerged as a potential adverse event associated with dalbavancin therapy.

Findings:

• Dalbavancin-induced fever is an inconsistently reported side effect.
• The prolonged half-life of dalbavancin complicates the management of drug-induced fever.
• This case underscores fever as a possible adverse reaction to dalbavancin.

Implications:

• Clinicians should consider fever as a potential dalbavancin side effect.
• Awareness of this adverse event is crucial for patient management.
• Further investigation into dalbavancin's safety profile regarding fever is warranted.